The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms.
about
Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label StudyBenign prostatic hyperplasia: from bench to clinicAntipsychotic-induced urinary dysfunction: anticholinergic effect or otherwise?Housing temperature influences the pattern of heat shock protein induction in mice following mild whole body hyperthermiaThe link between LUTS and ED: clinical and basic science evidence.Selecting therapy for maintaining sexual function in patients with benign prostatic hyperplasia.Role of alpha blocker therapy in chronic prostatitis/chronic pelvic pain syndrome: limited options with promising results.Chronic prostatitis/chronic pelvic pain syndrome: role of alpha blocker therapy.Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management.Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement.Non-Hormonal treatment of BPH/BOOSymptoms Predictive for Efficacy of Naftopidil in Patients with Benign Prostate Hyperplasia.A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia.Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.Doxazosin-induced up-regulation of alpha 1A-adrenoceptor mRNA in the rat lower urinary tract.Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.Terazosin-induced alterations in catalase expression and lipid peroxidation in the rat seminal vesicles.The effect of first dose of tamsulosin on flow rate and its predictive ability on the improvement of LUTS in men with BPH in the mid-term.Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms.Intravesical epinephrine preserves uroplakin II expression in urinary bladder from cyclophosphamide-induced rat cystitis.Long-term outcome of tamsulosin for patients with lower urinary tract symptoms according to the treatment response defined by lower urinary tract symptom outcomes score.Correlation between expression of α₁-adrenoceptor subtype mRNA and severity of lower urinary tract symptoms or bladder outlet obstruction in benign prostatic hyperplasia patients.
P2860
Q33735007-F6074159-1CA4-4A62-B678-A348F67043F7Q34216723-5B51A8EB-ACD3-4005-8B40-51226D13423AQ34524748-C8A62300-EAF8-4EA0-9940-28EB90E5FB12Q35121848-F622EA8F-3051-4327-A689-2BF7B3D28AF4Q35821086-47F92559-9719-4560-9284-4F38AF685077Q36206605-D1D9B815-6BFB-41E6-8CFC-EB547E003392Q36261483-A01F9961-DB19-43BA-A716-114DFA410CABQ36733501-3E201902-74AF-40F4-B345-871F4B30CCB6Q36737065-28E8E5E0-69C6-4326-BF3F-874D51ED360CQ38038271-A4548912-A851-4489-95B9-47748E7648CBQ38051005-52C7EEBE-28EA-4248-BEEB-279DCCAADA93Q38205423-A032573E-9B85-4242-827A-9AD053DDB416Q40202933-CBB63DBB-0280-4FFA-9DB5-59BB594874D6Q42565612-402C53EF-A0A7-4048-B495-1A4C518AB345Q44969928-845D1B2A-83A7-4ABF-98F2-BEB9D76441D9Q45169155-C0D04C6E-5A4F-4B70-939B-EA43A64E871BQ46654040-EB1F7809-11B8-46B9-B2EE-DAE07ED2FAA6Q46686217-5BC514D0-31B8-4662-B2BD-33669E1DF2C4Q48323154-9DDC8F2B-8800-4C53-BE2A-9359739FE704Q49478541-79A01FF1-5197-4CFA-A44B-B2B618F9BE22Q51336777-E068C774-AE29-46A7-B6BB-A4F528586463Q53153772-A72104DD-46F4-41BD-B636-45062F42690CQ53168781-8CDE13F0-EED5-4050-AA2D-E26A6152E4C9
P2860
The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms.
@ast
The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms.
@en
The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms.
@nl
type
label
The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms.
@ast
The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms.
@en
The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms.
@nl
prefLabel
The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms.
@ast
The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms.
@en
The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms.
@nl
P2860
P1433
P1476
The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms.
@en
P2093
Schwinn DA
P2860
P304
27-34; discussion 49-50
P356
10.1046/J.1464-410X.2001.00116.X
P478
88 Suppl 2
P577
2001-09-01T00:00:00Z